Joe Schroers-Martin, MD, on Follicular Lymphoma: Precursor Mutations May Be Detectable Years Before Diagnosis
2021 ASH Annual Meeting & Exposition
Joe Schroers-Martin, MD, of Stanford University, discusses his latest study findings, which show that follicular lymphoma driver mutations are detectable in blood and saliva years prior to a clinical diagnosis. These data build on previous work and suggest that researchers may be able to stratify people at elevated risk of clinical malignancy (Abstract 709).
The ASCO Post Staff
Michael R. Bishop, MD, of the University of Chicago, discusses insights from findings of the phase III BELINDA study, which may inform the design of future CAR T-cell trials, as well as the use of second-line tisagenlecleucel therapy in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (Abstract LBA-6).
The ASCO Post Staff
Daniel A. Ermann, MD, of the Huntsman Cancer Institute, University of Utah, discusses results from the largest retrospective study on outcomes utilizing radiotherapy in early-stage diffuse large B-cell lymphoma. Adding radiation to front-line multiagent chemotherapy was associated with a survival benefit for all patients with early-stage disease. An overall survival benefit was seen with the addition of radiation to front-line multiagent chemotherapy for patients with nodal involvement and those with specific extranodal involvement in the testes, thyroid, skin and soft tissue, and head and neck (Abstract 49).
The ASCO Post Staff
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses phase III results showing that gilteritinib and azacitidine led to significantly higher composite complete response rates in patients with newly diagnosed FLT3-mutant acute myeloid leukemia who are ineligible for intensive induction chemotherapy. Overall survival was similar to that of azacitidine alone (Abstract 700).
The ASCO Post Staff
Carsten Utoft Niemann, MD, PhD, of Copenhagen University Hospital, discusses a primary analysis of the phase II Vision HO141 trial, which showed the feasibility of stopping and restarting ibrutinib and venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia who have undetectable measurable residual disease. A favorable benefit-risk profile was demonstrated, with no new safety signals (Abstract 69).
The ASCO Post Staff
Tarek H. Mouhieddine, MD, of The Mount Sinai Hospital and The Icahn School of Medicine at Mount Sinai, discusses data that suggest patients with heavily pretreated, predominantly triple-class refractory multiple myeloma who relapse after treatment with bispecific antibodies may still have good outcomes when sequentially treating with other immunologic treatments (Abstract 821).
